IQVIA (NYSE:IQV) Given New $255.00 Price Target at UBS Group

IQVIA (NYSE:IQV) had its price target reduced by UBS Group from $260.00 to $255.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other analysts also recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Redburn Atlantic initiated coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Morgan Stanley decreased their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Truist Financial reduced their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Price Performance

Shares of IQV opened at $208.13 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. The firm’s fifty day simple moving average is $200.53 and its 200-day simple moving average is $219.80. The firm has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.25 and a beta of 1.48. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts forecast that IQVIA will post 10.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On IQVIA

Hedge funds have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA in the third quarter valued at approximately $27,000. Synergy Asset Management LLC acquired a new stake in IQVIA during the 4th quarter valued at $33,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. lifted its position in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 99 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.